Two trade names of deferasirox (Osveral® and Exjade®) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial

BACKGROUND: Beta-thalassemia major patients typically require chronic transfusion and iron-chelating agents to reduce serum iron overload. Osveral(®) is an available Iranian brand name of deferasirox used by majority of thalassemic patients. The aim of this study was to compare the efficacy of Osver...

Descripción completa

Detalles Bibliográficos
Autores principales: Rafati, Mohammadreza, Karami, Hossein, Lashtoo-Aghaee, Bita, Lashtoo-Aghaee, Bahareh, Dabirian, Mojdeh, Avan, Razieh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Babol University of Medical Sciences 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797811/
https://www.ncbi.nlm.nih.gov/pubmed/35178209
http://dx.doi.org/10.22088/cjim.13.1.61

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797811/
https://www.ncbi.nlm.nih.gov/pubmed/35178209
http://dx.doi.org/10.22088/cjim.13.1.61

Ejemplares similares